Please ensure Javascript is enabled for purposes of website accessibility

Why Iovance Biotherapeutics Soared 40% In June

By James Brumley - Jul 8, 2021 at 2:24AM

Key Points

  • Flagship trial drug Lifileucel continues to show promise despite regulatory setbacks.
  • The resignation of CEO Maria Fardis seems to have brought all the prospective selling to a head, setting up a rebound.
  • Shares are now trading well under recent levels, as well as 38% below the consensus target of $40.31.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon.

What happened

Shares of Iovance Biotherapeutics (IOVA -2.87%) gained 40.1% last month, according to numbers from S&P Global Market Intelligence. The move, largely driven by an update on a key clinical trial, reverses a downtrend that had been underway since February.

So what

Iovance Biotherapeutics may be one of the most promising names in the field of immuno-oncology, but that didn't prevent the stock from losing 70% of its value between February's high and May's low.

A concerning fourth-quarter update kicked off the cascade of selling that ended (ironically enough) in May, when Iovance's CEO Maria Fardis resigned following word that the prospective approval of its tumor-fighting candidate Lifileucel had been delayed...again. In this particular case, however, the stock's plunge in response to the news also flushed out the last of the prospective sellers, priming shares for a rebound.

A person in a business suit plots a rising chart of range bars on a digital screen.

Image source: Getty Images.

That much-needed rebound catalyst materialized on June 4, when the company posted updated efficacy data for the beleaguered drug as a treatment for a targeted segment of melanoma patients. Specifically, for advanced melanoma patients who are immune checkpoint inhibitor (ICI)-naive, the combination of Lifileucel and pembrolizumab demonstrates an overall response rate of 86%, and a complete response rate of 43%.

In simpler terms, delayed or not, the drug holds promise that the market seems to have lost sight of earlier in the year.

Now what

Biotech stocks are already difficult enough to trade. Pre-revenue biotech names like Iovance Biotherapeutics are even trickier to handle. Drama like unexpected CEO exits and approval delays makes such matters even more complicated.

Eventually, though, the risk-adjusted value of a company's pipeline -- its complete pipeline -- is reflected in the stock's price. That's what's starting to happen now for Iovance shares.

The stock soared for the better part of 2020, but perhaps sensing something wasn't quite right early this year, traders sold shares for most of 2021 to date; Fardis' resignation served as something of a capitulation. Now the actual potential of Lifileucel as a melanoma treatment is coming back into focus, along with the company's eight other trials and five other therapies in development. The market likes what it sees.

Better still, with shares well below February's high (near $53 per share) as well as under the consensus target of $40.31, there's lots of room for the stock to continue making bullish progress directly from its current price of around $25 per share.

James Brumley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
IOVA
$12.18 (-2.87%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.